期刊
GUT
卷 64, 期 3, 页码 438-446出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2014-307008
关键词
-
资金
- MSD
- Centocor
- Janssen
- Nestle Nutrition Institute
- Danone
- Mead Johnson
- Shire
- AbbVie
- Optimer
- Astra Zeneca
- Johnson and Johnson
- Janssen Canada
- Nutricia
- Helsinki University Central Hospital
- Sigrid Juselius Foundation
- Signe and Ane Gyllenberg Foundation
- Finnish Foundation for Paediatric Research
- Hospira
- Tillotts Pharma
- Janssen Biologics
- Merck
- Nestle
- BMS
- HSC (PUCAI)
- Abbott
- MRC [G0800675, G1002033] Funding Source: UKRI
- Medical Research Council [G0800675, G1002033] Funding Source: researchfish
- Medical Research Foundation [C0482] Funding Source: researchfish
Objective Although paediatric-onset IBD is becoming more common, few medications have a registered paediatric indication. There are multiple hurdles to performing clinical trials in children, emphasising the importance of choosing an appropriate outcome measure, which can facilitate enrolment, and thereby also drug approval. The aim of this consensus statement is to highlight paediatric specific issues and key factors critical for the optimal conduct of paediatric IBD trials. Design The Paediatric European Crohn's and Colitis Organisation (ECCO) committee has established an international expert panel to determine the best outcome measures in paediatric IBD, following a literature search and a modified Delphi process. All recommendations were endorsed by at least 80% agreement. Results Recognising the importance of mucosal healing (MH), the panel defined steroid-free MH as primary outcome measure for all drugs of new category with one or two postintervention endoscopies per trial (at 8-12 weeks and/or 54 weeks). Since endoscopic evaluation is a barrier for recruitment in children, trials with medications already shown to induce MH in children or adults, could use paediatric-specific disease activity scores as primary outcome, including a modified Paediatric Crohn's Disease Activity Index in Crohn's disease and the Paediatric Ulcerative Colitis Activity Index in UC. Secondary outcomes should include safety issues, MR enterography-based damage and inflammatory scores (in Crohn's disease), faecal calprotectin, quality of life scales, and a patient-reported outcome. Conclusions It is crucial to perform paediatric trials early in the development of new drugs in order to reduce off-label use of IBD medication in children. The thoughtful choice of feasible and standardised outcome measures can help move us towards this goal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据